Zacks Investment Research upgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning. The brokerage currently has $0.75 target price on the biotechnology company’s stock.

According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “

A number of other equities research analysts have also recently commented on the company. Maxim Group set a $3.00 target price on Actinium Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, November 14th. Roth Capital reissued a buy rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. HC Wainwright reaffirmed a buy rating and set a $6.00 price objective on shares of Actinium Pharmaceuticals in a research report on Monday, October 23rd. Finally, B. Riley initiated coverage on Actinium Pharmaceuticals in a research report on Wednesday, December 6th. They set a buy rating and a $2.75 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and a consensus price target of $3.75.

Actinium Pharmaceuticals (ATNM) traded down $0.02 during midday trading on Tuesday, hitting $0.71. The stock had a trading volume of 292,400 shares, compared to its average volume of 570,192. Actinium Pharmaceuticals has a 52-week low of $0.54 and a 52-week high of $1.72. The stock has a market capitalization of $59.22, a PE ratio of -1.51 and a beta of 41.30.

TRADEMARK VIOLATION WARNING: “Actinium Pharmaceuticals (ATNM) Upgraded at Zacks Investment Research” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/01/19/actinium-pharmaceuticals-atnm-upgraded-at-zacks-investment-research.html.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Get a free copy of the Zacks research report on Actinium Pharmaceuticals (ATNM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.